Literature DB >> 7323401

[The pharmacokinetics of isoniazid in children (author's transl)].

C Advenier, A Saint-Aubin, P Scheinmann, J Paupe.   

Abstract

The purpose of this study, which involved 134 children aged between 0.5 and 17 years, was to investigate the metabolism of isoniazid (INH) in children and to provide guide-lines for dosage. The distribution of slow (55,5%) and fast (44,5%) acetylators was the same in children as in adults. However, the mean of INH inactivation index were lower (0.23 and 0.48) while distribution volumes, (1.30 +/- 0.06 and 1.57 +/- 0.17 1/kg) and total plasma clearances (5.39 +/- 0.43 and 14.7 +/- 1.5 ml/Kg/min) were higher than in adults. Plasma half-lives were similar in children and adults. These results indicate that INH is more rapidly metabolized in children owing, it is suggested to a higher liver weight : body weight ratio and to a more pronounced first pass effect. The doses of INH therefore must be higher in children and strictly adapted to each individual.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7323401

Source DB:  PubMed          Journal:  Rev Fr Mal Respir        ISSN: 0301-0279


  4 in total

1.  Pharmacokinetics of isoniazid: influence of age.

Authors:  M F Kergueris; M Bourin; C Larousse
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Authors:  S Thee; J A Seddon; P R Donald; H I Seifart; C J Werely; A C Hesseling; B Rosenkranz; S Roll; K Magdorf; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

3.  Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

Authors:  H S Schaaf; D P Parkin; H I Seifart; C J Werely; P B Hesseling; P D van Helden; J S Maritz; P R Donald
Journal:  Arch Dis Child       Date:  2005-06       Impact factor: 3.791

4.  N-acetylation in healthy and diseased children.

Authors:  E Hadasová; V Brysová; E Kadlcáková
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.